Optimus Announces Interim Clinical Results from Phase III Clinical Trials of Molnupiravir Conducted in India
By 90 Comments on Optimus Announces Interim Clinical Results from Phase III Clinical Trials of Molnupiravir Conducted in India

Hyderabad (Telangana) [India], July 21: Optimus Pharma on Sunday submitted the interim result of Phase III Clinical Trials for orally administered Molnupiravir capsules on patients with Mild Covid-19 patients. With an acute shortage of antiviral drugs in the market against the SARS-CoV-2 infection, it is imperative that more drugs with potent antiviral activity against SARS-CoV-2 be introduced.

In a statement, the MD and Chairman Dr. D Srinivasa Reddy had declared that Optimus pharma has internally developed the active pharmaceutical ingredient (API) and the formulations for the product and had obtained approval for conducting Phase 3 Clinical Trial.

As per the clinical trial protocol approved, 1218 subjects with mild COVID-19 will be randomised in the study in a 1:1 ratio to Molnupiravir with the standard of care, or standard of care alone. The treatment duration is a maximum of 05 days and the total study duration will be a maximum of 28 days from randomisation.

“Optimus is all geared to immediately begin manufacturing of Molnupiravir for COVID-19 patients in India. The interim results on 353 patients have shown promising results of Molnupiravir. The drug has been successful in reducing viral load effectively with RT-PCR negativity achieved 78.3 % in the test arm compared to 48.4% in the standard of care arm on Day 5. Day 10 and Day 14 of the treatment duration have also given excellent results wherein the remaining patients have successfully achieved RT-PCR negativity. The trial has also revealed clinical improvement in a significantly high proportion of patient’s health. The safety of the drug has also been established with no observed side effects, co-morbidity, or morbidity observed during and after the treatment duration,” Chairman & Managing Director – Dr. D Srinivasa Reddy said.

Optimus has approached the Drugs Controller General of India (DCGI) to seek Emergency Use Authorization for Molnupiravir in India.

Optimus Pharma is committed to serve the nation and fight back the pandemic to restore normalcy in the lives of people affected by COVID-19 at the earliest. With the cooperation of the government and our stakeholders, and a special thanks to the Subject Expert Committee of the CDSCO for their valuable contribution and their recommendations to the project, we hope to deliver the product in India by leveraging our solid distribution strength across the country.

Covid-19D Srinivasa ReddyDCGIDrugs Controller General of IndiaInterim Clinical ResultsMolnupiravirOptimus PharmaPhase III Clinical TrialsSARS-CoV-2

90 Replies to “Optimus Announces Interim Clinical Results from Phase III Clinical Trials of Molnupiravir Conducted in India”

  27. Pingback: non flash sex games

  64. I was wondering if you ever considered changing the page layout of your site?
    Its very well written; I love what youve got to say. But maybe you could
    a little more in the way of content so people could connect
    with it better. Youve got an awful lot of text for
    only having 1 or 2 pictures. Maybe you could space it out better?

  69. Somebody essentially assist to make significantly articles
    I might state. That is the very first time I frequented
    your website page and up to now? I amazed with the research you made to create this particular
    submit extraordinary. Excellent job!

  71. My brother suggested I might like this blog. He was entirely right.
    This post actually made my day. You can not imagine simply how much time I had spent for this info!
    Thanks!

  72. Hey there! Someone in my Myspace group shared
    this website with us so I came to look it over.
    I’m definitely enjoying the information. I’m book-marking
    and will be tweeting this to my followers! Wonderful blog and brilliant design and style.

  76. If some one wishes expert view regarding blogging then i propose him/her
    to pay a visit this webpage, Keep up the pleasant work.

  77. whoah this blog is fantastic i like studying your posts.

    Keep up the good work! You already know, lots of people are hunting round for this info, you can help them greatly.

  79. hey there and thank you for your info – I’ve definitely picked up something new from right here.
    I did however expertise several technical points using
    this web site, since I experienced to reload the web site many times previous
    to I could get it to load correctly. I had been wondering if your web hosting is OK?

    Not that I am complaining, but sluggish loading instances times will sometimes affect your placement in google and could
    damage your high-quality score if ads and marketing with Adwords.
    Anyway I’m adding this RSS to my email and can look out for much more of your respective
    intriguing content. Ensure that you update this again very soon.

  81. Unquestionably believe that which you said. Your favorite justification seemed
    to be on the internet the easiest thing to be aware of.
    I say to you, I certainly get annoyed while people think about worries that they plainly don’t know about.
    You managed to hit the nail upon the top and also defined out
    the whole thing without having side-effects , people can take a signal.
    Will likely be back to get more. Thanks

  88. Pingback: sbo

Leave a Reply

Your email address will not be published.